Do SMS/e-mail reminders increase influenza vaccination of rheumatoid arthritis patients under anti-TNF: a nested randomized controlled trial in the ART e-cohort

Rheumatology (Oxford). 2025 May 1;64(5):2496-2504. doi: 10.1093/rheumatology/keae599.

Abstract

Objectives: The objectives of this study were to evaluate the effectiveness of short message service (SMS) and/or email reminders in improving influenza vaccination coverage rates among RA patients treated with anti-TNF therapies, and to identify factors associated with vaccination.

Methods: This study was a nested randomized controlled trial in the ART e-cohort, an ongoing French nationwide multicentre prospective cohort of RA patients treated with anti-TNF therapy. Patients were 1:1 randomized, with stratification on age. The intervention consisted of regular reminders via SMS and/or emails to get vaccinated against influenza during the vaccination campaign. At the end, all participants received a questionnaire. The primary outcome was influenza vaccination coverage. Secondary outcomes included the vaccination coverage before and after the COVID-19 pandemic, and factors associated with vaccination.

Results: Between October 2021 and April 2022, 446 participants were randomized (224 to the intervention group and 222 to the control group). Among them, 325 (73%) reported their vaccination status and 221 (68%) were vaccinated against influenza: 116/158 (73%) in the intervention group, vs 105/167 (63%) in the control group (relative risk 1.08; 95% CI 0.95-1.23). The vaccination coverage before and after the COVID-19 pandemic did not differ (72% vs 72%; 95% CI -8% to 8%). Age ≥65 years [odds ratio (OR) 6.25; 95% CI 2.88-13.60] and previous influenza vaccination in the years before inclusion (OR 7.81; 95% CI 4.36-14.02) were associated with higher rates of vaccination.

Conclusion: SMS and/or e-mail reminders did not significantly improve influenza vaccination rates in our cohort. The COVID-19 pandemic did not substantially impact the influenza vaccination coverage. Our results might be counterbalanced by an already high vaccination coverage.

Trial registration: ClinicalTrials.gov, http://clinicaltrials.gov, NCT05220423, NCT03062865.

Keywords: bDMARDs; influenza; rheumatoid arthritis; vaccine.

Publication types

  • Randomized Controlled Trial
  • Multicenter Study

MeSH terms

  • Adult
  • Aged
  • Antirheumatic Agents* / therapeutic use
  • Arthritis, Rheumatoid* / drug therapy
  • COVID-19 / epidemiology
  • COVID-19 / prevention & control
  • Electronic Mail*
  • Female
  • France
  • Humans
  • Influenza Vaccines* / administration & dosage
  • Influenza Vaccines* / therapeutic use
  • Influenza, Human* / prevention & control
  • Male
  • Middle Aged
  • Prospective Studies
  • Reminder Systems*
  • SARS-CoV-2
  • Text Messaging*
  • Vaccination Coverage* / statistics & numerical data
  • Vaccination* / statistics & numerical data

Substances

  • Influenza Vaccines
  • Antirheumatic Agents

Associated data

  • ClinicalTrials.gov/NCT05220423
  • ClinicalTrials.gov/NCT03062865